Behavioural disorders in demented elderly patients. Current issues in pharmacotherapy

CNS Drugs

Volumn 6, Issue 4, 1996, Pages 280-300

  Herrmann, Nathan ^a,b   Lanctôt, Krista L ^b,c   Naranjo, Claudio A ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BUSPIRONE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; CYPROTERONE; DIPHENHYDRAMINE; HALOPERIDOL; LITHIUM; LORAZEPAM; LOXAPINE; MESORIDAZINE; NEUROLEPTIC AGENT; OXAZEPAM; PHENYTOIN; PINDOLOL; PROPRANOLOL; RISPERIDONE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TACRINE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROIC ACID;

BEHAVIOR DISORDER; CAREGIVER; DEMENTIA; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029804593     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199606040-00004     Document Type: Review

References (171)

1. Cross PS, Gurland GJ. The epidemiology of dementing disorders. Washington: Office of Technology Assessment, US Congress, 1986
2. Erkinjuntti T, Wikström J, Palo J, et al. Dementia among medical inpatients: evaluation of 2000 consecutive admissions. Arch Intern Med 1986; 146: 1923-6
3. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994; 84: 1261-4
4. Sapienza A. AD and related dementias: whose burden? Pharm News 1995; 2 (1): 27-8
5. Eagles JM, Beattie JAG, Restall DB, et al. Relation between cognitive impairment and early death in the elderly. BMJ 1990; 300: 239-440
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
7. Civil RH, Whitehouse PJ, Lanska DJ, et al. Degenerative dementias. In: Whitehouse PJ, editor. Dementia, Philadelphia: F.A. Davis Company, 1993: 167-214
8. Yeager BF, Farnett LE, Ruzicka SA. Management of the behavioral manifestations of dementia. Arch Intern Med 1995 Feb 13; 155: 250-60
9. DiMascio A, Shader RI. Behavioral toxicity. Part I: definition and Part II: psychomotor functions. In: Shader RI, Dimascio A, editors. Psychotropic drug side effects. Baltimore: The Williams and Wilkins Company, 1970: 124-48
10. Raskind MA. Geriatric psychopharmacology: management of late-life depression and the non-cognitive behavioral disturbances of Alzheimer's disease. In: Dunner DL, editor. The psychiatric clinics of North America. Psychopharmacology II. Philadelphia: W.B. Saunders Company, 1993: 815-27
11. Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44 (12): 2308-14
12. Reisberg B. Behavioral pathology in Alzheimer's disease rating scale (BEHAVE-AD). J Clin Psychiatry 1987 May; 48 Suppl.: 9-15
13. Cohen-Mansfield J, Billig N. Agitated behaviours in the elderly. I. A conceptual review. J Am Geriatr Soc 1986; 34: 711-21
14. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol 1989; 44 (3): M77-84
15. Goldstein K. The after-effects of brain injuries in war: their evaluation and treatment. New York: Grune and Stratton, 1942
16. Rabins PV, Folstein MF. Delirium and dementia: diagnostic criteria and fatality rates. Br J Psychiatry 1982; 140: 149-53
17. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48 Suppl. 5: 9-15
18. Merriam AE, Aronson MK, Gaston P. The psychiatric symptoms of Alzheimer's disease. J Am Geriatr Soc 1988; 36: 7-12
19. Teri L, Larson FB, Reifler BV. Behavioral disturbance in dementia of the Alzheimer's type. J Am Geriatr Soc 1988; 36: 1-6
20. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989; 146 (5): 577-87
21. Eastwood MR. Abnormal behaviour associated with dementia. Int Psychiatry Today 1994; 4: 8-10
22. Reisberg B, Ferris SH, de Leon MJ, et al. Global deterioration scale (GDS). Psychopharmacol Bull 1988; 24: 661-3
23. Teri L, Rabins P, Whitehouse P, et al. Management of behaviour disturbance in Alzheimer disease: current knowledge and future direction. Alzheimer Dis Assoc Disord 1992; 6 (2): 77-88
24. Kunik ME, Yudofsky SC, Silver JM, et al. Pharmacologic approach to management of agitation associated with dementia. J Clin Psychiatry 1994; 55 (2 Suppl.): 13-7
25. Whall AL, Gillis GL, Yankou D, et al. Disruptive behaviour in elderly nursing home residents: a survey of nursing staff. J Gerontol Nursing 1992 Oct; 12: 13-7
26. Zimmer JG, Watson N, Treat A. Behavioral problems among patients in skilled nursing facilities. Am J Public Health 1984; 74 (10): 1118-21
27. Swearer JM, Drachman DA, O'Donnell BF, et al. Troublesome and disruptive behaviours in dementia; relationship to diagnosis and disease severity. J Am Geriatr Soc 1988; 36 (9): 784-90
28. Reisberg B. Memory dysfunction and dementia: diagnostic considerations. In: Salzman C, editor. Clinical geriatric psychopharmacology. 2nd ed. Baltimore: Williams & Wilkins, 1992: 255-76
29. Rubin EH, Kinscherf DA. Psychopathology of very mild dementia of the Alzheimer type. Am J Psychiatry 1989; 146: 1017-21
30. Sultzer DL, Levin HS, Mahler ME, et al. Assessment of cognitive, psychiatric, and behavioral disturbances in patients with dementia: the neurobehavioral rating scale. J Am Geriatr Soc 1992; 40: 549-55
31. Mega MS, Cummings JL, Foorello T, et al. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46 (1): 130-5
32. Sultzer DL, Levin HS, Mahler ME, et al. A comparison of psychiatric symptoms in vascular dementia and Alzheimer's disease. Am J Psychiatry 1993; 150 (12): 1806-12
33. Lopez OL, Becker JT, Brenner RP, et al. Alzheimer's disease with delusions and hallucinations: neuropsychological and electroencephalographic correlates. Neurology 1991; 41: 906-12
34. Förstl H, Burns A, Jacoby R, et al. Neuroanatomical correlates of clinical misidentification and misperception in senile dementia of the Alzheimer type. J Clin Psychiatry 1991; 52 (6): 268-71
35. Kotrla KJ, Chacko RC, Harper RG, et al. SPECT findings on psychosis on Alzheimer's disease. Am J Psychiatry 1995; 152: 1470-5
36. Starkstein SE, Vàsquez S, Petracca G, et al. A SPECT study of delusions in Alzheimer's disease. Neurology 1994 Nov; 44: 2055-9
37. Sultzer DL, Mahler ME, Mandelker MA, et al. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1995; 7 (4): 476-84
38. Zubenko GS, Moossy J, Martinez AJ, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 1991; 48: 619-24
39. Förstl H, Burns A, Luthert P, et al. Clinical and neuropathological correlates of depression in Alzheimer's disease. Psychol Med 1992; 22: 877-84
40. Zubenko GS, Moossy J. Major depression in primary dementia. Clinical and neuropathologic correlates. Arch Neurol 1988; 45: 1182-6
41. Jaeschke R, Gyuyatt GH, Cook D. Quality of life instruments in the evaluation of new drugs. PharmacoEconomics 1992; 1 (2): 84-94
42. Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. JAMA 1982; 248: 333-5
43. Gaspar D. Hollymoor hospital dementia service: analysis of outcome of 230 consecutive referrals to a psychiatric-hospital dementia service. Lancet 1980; I: 1402-5
44. Petrie WM, Lawson EC, Hollender MH. Violence in geriatric patients. JAMA 1982; 248 (4): 443-4
45. Gleason RP, Schneider LS. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. J Clin Psychiatry 1990; 51 (3): 115-8
46. Ryden MB. Aggressive behaviour in persons with dementia who live in the community. Alzheimer Dis Assoc Disord 1988; 2 (4): 342-55
47. Cohen GD. Biopsychiatry in Alzheimer's disease. In: Lawton MP, editor. Annual review of gerontology and geriatrics, vol 9. New York: Springer Verlag, 1989: 216-31
48. Howard K, Rockwood K. Quality of life in Alzheimer's disease. Dementia 1995; 6: 113-6
49. Lawton M. Quality of life in Alzheimer's disease. Alzheimer Disease Assoc Disord 1994; 8 Suppl. 3: 138-50
50. Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995; 15 (4): 243-9
51. Herrera JN, Sramek JJ, Costa JF, et al. High potency neuroleptics and violence in schizophrenics. J Nerv Ment Dis 1988; 176 (9): 558-61
52. Learoyd BM. Psychotropic drugs and the elderly patient. Med J Aust 1972; 1: 1131-3
53. Thapa PB, Meador KG, Gideon P, et al. Effects of antipsychotic withdrawal in elderly nursing home residents. J Am Geriatr Soc 1994; 42 (3): 280-6
54. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141 (11): 1356-64
55. Levin HS, High WM, Goethe KE, et al. The neurobehavioral rating scale: assessment of the behavioral sequelae of head injury by the clinician. J Neurol Neurosurg Psychiatry 1987; 50: 183-93
56. Tariot PN, Mack JL, Patterson MB, et al. The behaviour rating scale for dementia of the consortium to establish a registry for Alzheimer's disease. Am J Psychiatry 1995 Sep; 152: 1349-57
57. Cohen-Mansfield J. Agitated behaviours in the elderly. II. Preliminary results in the cognitively deteriorated. J Am Geriatr Soc 1986; 34: 722-7
58. Rosen J, Burgio L, Kollar M, et al. The Pittsburgh agitation scale - a user-friendly instrument for rating agitation in dementia patients. Am J Geriatr Psychiatry 1994; 2 (1): 52-9
59. Weiner MF, Koss E, Wild KV, et al. Measures of psychiatric symptoms in Alzheimer patients: a review. Alzheimer Dis Assoc Disord 1996; 10 (1): 20-30
60. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38 (5): 553-63
61. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44
62. Hachinski V, Iliff L, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632-7
63. Hesse K, Driscoll A, Jacobson S. Neuroleptic prescriptions for acutely ill geriatric patients. Arch Intern Med 1993 Nov; 153: 2581-7
64. Avorn J, Dreyer P, Connelly K, et al. Use of psychoactive medication and the quality of care in rest homes. Findings and policy implications of a state-wide study. N Engl J Med 1989; 320: 227-32
65. Gurwitz JH, Sourerai SB, Avorn J. Improving medication prescribing and utilization in the nursing home. J Am Geriatr Soc 1990; 38 (5): 542-52
66. Lantz MS, Louis A, Lowenstein G, et al. A longitudinal study of psychotropic prescriptions in a teaching nursing home. Am J Psychiatry 1990; 147 (12): 1637-9
67. Semla TP, Palla K, Poddig B, et al. Effect of the Omnibus Reconciliation Act 1987 on antipsychotic prescribing in nursing home residents. J Am Geriatr Soc 1994; 42 (6): 648-52
68. Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med 1991; 151: 1825-32
69. Helms PM. Efficacy of antipsychotics in the treatment of the behavioral complications of dementia: a review of the literature. J Am Geriatr Soc 1985; 33 (3): 206-9
70. Sunderland T, Silver MA. Neuroleptics in the treatment of dementia. Int J Geriatr Psychiatry 1988; 3: 79-88
71. Carlyle W, Ancill RJ, Sheldon L. Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. Int Clin Psychopharmacol 1993; 8: 103-8
72. Finkel SI, Lyons JS, Anderson RL, et al. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. Int J Geriatr Psychiatry 1995; 10: 129-36
73. Raskind MA, Risse SC. Antipsychotic drugs and the elderly. J CHn Psychiatry 1986; 46 (5 Suppl.): 17-22
74. Risse SC, Barnes R. Pharmacologic treatment of agitation associated with dementia. J Am Geriatr Soc 1986; 34: 368-76
75. Barnes R, Veith R, Okimoto J, et al. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry 1982; 139: 1170-4
76. Lanctôt KL, Mittmann N, Liu BA, et al. Efficacy and safely of neuroleptics in behavioral disorders associated with dementia [abstract]. Clin Pharmacol Ther 1995; 57 (2): 199
77. Sweet RA, Pollock BG, Mulsant BH, et al. Prolactin response to neuroleptic challenge in late-life psychosis. Psychopharmacol Bull 1995; 31 (4): 651-7
78. Petrie WM, Ban TA, Berney S, et al. Loxapine in psychogeriatrics: a placebo- and standard-controlled clinical investigation. J Clin Psychopharmacol 1982; 2: 122-6
79. Oberholzer AF, Hendriksen C, Monsch AU, et al. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychogeriatr 1992; 4 (2): 187-95
80. Pitner JK, Mintzer JE, Pennypacker LC, et al. Efficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry 1995; 56 (5): 180-5
81. Ball CJ. The use of clozapine in older people. Int J Geriatr Psychiatry 1992; 7: 689-92
82. Mertens C, Heylen SL. Risperidone in psychogeriatric patients with behavioral disturbances: an open long-term follow-up study. Report for trial RIS-BEL-13. Janssen Research Foundation, 1990 (Data on file)
83. Madhusoodanan S, Brenner R, Araujo L, et al. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995; 56 (11): 514-8
84. Yudofsky SC, Silver JM, Hales RE. Pharmacologic management of aggression in the elderly. J Clin Psychiatry 1990; 51 (10 Suppl.): 22-8
85. Simpson GM, Pi EH, Sramek JJJ. Adverse effects of antipsychotic agents. Drugs 1981; 21: 138-51
86. Zubenko GS, Lipinski JF, Cohen BM, et al. Comparison of metoprolol and propranolol in the treatment of akathisia. Psychiatry Res 1984; 11: 143-9
87. Hayes PE, Schulz SC. The use of beta-adrenergic blocking agents in anxiety disorders and schizophrenia. Pharmacotherapy 1983; 3: 101-7
88. Yudofsky SC, Silver JM, Schneider SE. Pharmacologic treatment of aggression. Psychiatr Ann 1987; 27: 397-407
89. Petrie WM, Ban TA. Propranolol in organic agitation [letter]. Lancet 1981; I: 324
90. Greendyke RM, Schuster DB, Wooton JA. Propranolol in the treatment of assaultive patients with organic brain disease. J Clin Psychopharmacol 1984; 4: 282-5
91. Greendyke RM, Kanter DR, Schuster DB, et al. Propranolol treatment of assaultive patients with organic brain disease. J Nerv Ment Dis 1986; 174: 290-4
92. Greendyke RM, Kanter DR. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry 1986; 47: 423-6
93. Greendyke RM, Berkner JP, Wehster JC, et al. Treatment of behavioral problems with pindolol. Psychosomatics 1989; 30: 161-5
94. Weiler PG, Mungas D, Bernick C. Propranolol for the control of disruptive behaviour in senile dementia. J Geriatr Psychiatr Neurol 1988; 1: 226-30
95. Smith DA, Perry PJ. Non-neuroleptic treatment of disruptive behaviour in organic mental syndromes. Ann Pharmacother 1992; 26: 1400-8
96. Silver JM, Yudofosky SC, Kogan M, et al. Elevation of thioridazine plasma levels by propranolol. Am J Psychiatry 1986; 143: 1290-2
97. Weiler PG, Goodman TA. The use of propranolol in Alzheimer's disease patients with disruptive behaviour. Curr Ther Res 1987; 42: 364-74
98. Ratey JJ, Sorgi P, O'Driscoll GA, et al. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind placebo-controlled study. J Clin Psychiatry 1992; 53: 41-6
99. Sheard MH. Effect of lithium on human aggression. Nature 1971; 230: 113-4
100. Schneider LS, Sobin PB. Non-neuroleptic medications in the management of agitation in Alzheimer's disease and other dementia: a selective review. Int J Geriatr Psychiatry 1991; 6: 691-708
101. Naranjo CA, Herrmann N, Mittmann N, et al. Recent advances in geriatric psychopharmacology. Drugs Aging 1995; 7: 184-202
102. Wragg RE, Jeste DV. Neuroleptics and alternative treatments. Psychiatr Clin North Am 1988; II: 195-213
103. Beber CR. Management of behaviour in the institutionalized aged. Dis Nerv Syst 1965; 26: 591-5
104. Chesrow EJ, Kaplitz SE, Vetra H, et al. Blind study of oxazepam in the management of geriatric patients with behavioral problems. Clin Med 1965; 72: 1001-5
105. Sanders JF. Evaluation of oxazepam and placebo in emotionally disturbed aged patients. Geriatrics 1965; 20: 739-46
106. Kirven LE, Montero EF. Comparison of thioridazine and diazepam in the control of non psychotic symptoms associated with senility: double-blind study. J Am Geriatr Soc 1973; 21: 546-51
107. Covington JS. Alleviating agitation, apprehension, and related symptoms in geriatric patients: a double-blind comparison of a phenothiazine and a benzodiazepine. South Med J 1975; 68: 719-24
108. Stotskey B. Multicenter study comparing thioridazine with diazepam and placebo in elderly non-psychotic patients with emotional and behavioral disorders. Clin Ther 1984; 6: 546-9
109. Coccaro EF, Kramer E, Zemishlany Z, et al. Pharmacologic treatment of non-cognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990; 147: 1640-5
110. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
111. Maletta GJ. Treatment of behavioral symptomatology of Alzheimer's disease, with emphasis on aggression: current clinical approaches. Int Psychogeriatr 1992; 4 Suppl. 1: 117-30
112. Stern RG, Duffelmeyer ME, Zemeshlani Z, et al. The use of benzodiazepines in the management of behavioral symptoms in demented patients. Psychiatr Clin North Am 1991; 14: 375-84
113. Freinhar JP, Alvarez WA. Clonazepam treatment of organic brain syndromes in three elderly patients. J Clin Psychiatry 1986; 47: 525-6
114. Smeraski PJ. Clonazepam treatment of multi-infarct dementia. J Geriatr Psychiatry Neurol 1988; I: 47-8
115. Ginsburg ML. Clonazepam for agitated patients with Alzheimer's disease. Can J Psychiatry 1991; 36: 237-8
116. Reifler BV, Teri L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry 1989; 146: 45-9
117. Peisah C, Brodaty H. Practical guidelines for the treatment of behavioral complications of dementia. Med J Aust 1994; 161: 558-63
118. Friedman R, Gryfe CI, Tal DT, et al. The noisy elderly patient: prevalence, assessment, and response to the antidepressant doxepin. J Geriatr Psychiatry Neurol 1992; 5: 187-91
119. Burke WJ, Folks DG, Roccaforte WH, et al. Serotonin reuptake inhibitors for the treatment of co-existing depression and psychosis in dementia of the Alzheimer's type. Am J Geriatr Psychiatry 1994; 2: 352-4
120. Reynolds CF, Perel JM, Kupfer DJ, et al. Open-trial to antidepressant treatment in elderly patients with mixed depression and cognitive impairment. Psychiatry Res 1987; 21: 111-22
121. Jenike MA. Monamine oxidase inhibitors as treatment for depressed patients with primary degenerative dementia (Alzheimer's disease). Am J Psychiatry 1985; 142: 763-4
122. Chan-Palay V. Depression and senile dementia of the Alzheimer's type: a role for moclobemide. Psychopharmacology 1992; 106 Suppl.: S137-9
123. Aisen PS, Johannessen DJ, Marin DB. Trazodone for behavioral disturbances in Alzheimer's disease. Am J Geriatr Psychiatry 1993; 1: 349-50
124. Houlihan DJ, Mulsant BH, Sweet RA, et al. A naturalistic study of trazodone in the treatment of behavioral complications of dementia. Am J Geriatr Psychiatry 1994; 1: 78-85
125. Lebert F, Pasquier F, Petit H. Behavioral effects of trazodone in Alzheimer's disease. J Clin Psychiatry 1994; 55: 536-8
126. Tejera CA, Saravoy SM. Treatment of organic personality syndrome with low-dose trazodone. J Clin Psychiatry 1995; 56: 374-5
127. Lawlor BA, Radcliffe J, Molchan SE, et al. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer's disease. Int J Geriatr Psychiatry 1994; 9: 55-9
128. Lebert F, Pasquier F, Petit H. Behavioral effects of fluoxetine in dementia of Alzheimer's type. Int J Geriatr Psychiatry 1994; 9: 590-1
129. Geldmacher DS, Waldman AJ, Doty L, et al. Fluoxetine in dementia of the Alzheimer's type: prominent adverse effects and failure to improve cognition [letter]. J Clin Psychiatry 1994; 55: 161
130. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. Br J Psychiatry 1990; 157: 894-901
131. Olafsson K, Jorgensen S, Jensen HV, et al. Fluvoxamine in the treatment of demented elderly patients: a double-blind placebo-controlled study. Acta Psychiatr Scand 1992; 851: 453-6
132. Sunderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994; 51: 607-15
133. Martini E, Pataky I, Szelagyi K, et al. Brief information on an early phase II study with deprenyl in demented patients. Pharmacopsychiatry 1987; 20: 256-7
134. Schneider LS, Gleason R, Zemansky MF, et al. A pilot study of low-dose L-deprenyl in Alzheimer's disease. J Geriatr Psychiatry Neurol 1991; 4: 143-8
135. Goad DL, Davis CM, Liem P, et al. The use of selegiline in Alzheimer's patients with behaviour problems. J Clin Psychiatry 1991; 52: 342-5
136. Tariot PN, Cohen RM, Sunderland T, et al. L-Deprenyl in Alzheimer's disease: preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatry 1987; 44: 427-33
137. Mangoni A, Grassi MP, Frattola L, et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer's disease. Eur Neurol 1991; 31: 100-7
138. Burke WJ, Roccaforte WH, Wengel SP, et al. L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 1993; 41: 1219-25
139. Post RM, Susan R, Weiss B. Sensitization, kindling, and carbamazepine: an update on their implications for the course of affective illness. Pharmacopsychiatry 1992; 25: 41-3
140. Leibovici A, Tariot PN. Carbamazepine treatment of agitation associated with dementia. J Geriatr Psychiatr Neurol 1988; 1: 110-2
141. Patterson JF. Carbamazepine for assaultive patients with organic brain disease. Psychosomatics 1987; 28: 579-81
142. Patterson JF. A preliminary study of Carbamazepine in the treatment of assaultive patients with dementia. J Geriatr Psychiatr Neurol 1988; 1: 21-3
143. Lemke MR. Effects of Carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. J Clin Psychiatry 1995; 56: 354-7
144. Chambers CA, Bain J, Rosbottom R, et al. Carbamazepine in senile dementia and overactivity - a placebo controlled double blind trial. Int Res Comm Sys Med Sci 1982; 10: 505-6
145. Tariot PN, Erb R, Leibovici A, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc 1994; 42: 1160-6
146. Yudofsky SC, Silver JM, Jackson W, et al. The overt aggression scale for the objective rating of verbal and physical aggression. Am J Psychiatry 1986; 143: 35-9
147. Lefkowitz MM. Effects of diphenylhydantoin on disruptive behaviour. Arch Gen Psychiatry 1969; 20: 643-51
148. Conners CK, Kramer R, Rothschild GH, et al. Treatment of young delinquent boys with diphenylhydantoin sodium and methylphenidate. Arch Gen Psychiatry 1971; 24: 156-60
149. Mellow AM, Solano-Lopez C, Davis S. Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatry Neurol 1993; 6: 205-9
150. Sandborn WD, Bendfeldt F, Hamdy R. Valproic acid for physically aggressive behaviour in geriatric patients. Am J Geriatr Psychiatry 1995; 3: 239-42
151. Sival RC, Haffmans PMJ, Van Gent PP, et al. The effects of sodium valproate on disturbed behaviour in dementia. J Am Geriatr Soc 1994; 42: 906-7
152. Mazure CM, Druss BG, Cellar JS. Valproate treatment of older psychotic patients with organic mental syndromes and behavioral dyscontrol. J Am Geriatr Soc 1992; 40: 914-6
153. Colenda CC. Buspirone in treatment of agitated demented patient [letter]. Lancet 1988; II: 1169
154. Herrmann N, Eryavec G. Buspirone in the management of agitation and aggression associated with dementia. Am J Geriatr Psychiatry 1993; 1: 249-53
155. Sakauye KM, Camp CJ, Ford PA. Effects of buspirone on agitation associated with dementia. Am J Geriatr Psychiatry 1993; 1: 82-4
156. Levy MA, Burgio LD, Sweet R, et al. A trial of buspirone for the control of disruptive behaviours in community dwelling patients with dementia. Int J Geriatr Psychiatry 1994; 9: 841-8
157. Bradford JMW. Organic treatments for the male sexual offender. Behav Sci Law 1985; 3: 355-75
158. Cooper AJ. Progestogens in the treatment of male sexual offenders: a review. Can J Psychiatry 1986; 31: 73-9
159. Cooper AJ. Medroxyprogesterone acetate (MPA) treatment of sexual acting out in men suffering from dementia. J Clin Psychiatry 1987; 48: 368-70
160. Kyomen HH, Nobel KW, Wei JY. The use of estrogen to decrease aggressive physical behaviour in elderly men with dementia. J Am Geriatr Soc 1991; 39: 1110-2
161. Nadal M, Allgulander S. Normalization of sexual behaviour in a female with dementia after treatment with cyproterone. Int J Geriatr Psychiatry 1993; 8: 265-7
162. Rich SS, Ovsiew F. Leuprolide acetate for exhibitionism in Huntington's disease. Mov Disord 1994; 9: 353-7
163. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 2523-9
164. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind placebo-controlled multicentre study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327: 1253-9
165. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-91
166. Cummings JL, Gorman DG, Shapiro J. Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry 1993; 33: 536-41
167. Beck CK, Shue VM. Interventions for treating disruptive behaviour in demented elderly people. Nurs Clin North Am 1994; 29: 143-55
168. Rapp MS, Flint AJ, Herrmann N, et al. Behavioral disturbances in the demented elderly: phenomenology, pharmacotherapy, and behavioral management. Can J Psychiatry 1992; 37: 651-7
169. Rewilak D. Behaviour management strategies. In: Rewilak D, Conn DK, Herrmann N, et al., editors. Practical psychiatry in the nursing home. Seattle: Hogrefe & Huber, 1992: 193-216
170. Nilsson K, Palmerstierna T, Wistedt B. Aggressive behaviour in hospitalized psychogeriatric patients. Acta Psychiatr Scand 1988; 78: 172-5
171. Palmstierna T, Wistedt B. Staff observation aggression scale, SOAS. Presentation and evaluation. Acta Psychiatr Scand 1987; 76: 657-3